Legend Biotech (LEGN) Scheduled to Post Earnings on Monday

Legend Biotech (NASDAQ:LEGN) is scheduled to release its earnings data before the market opens on Monday, May 13th. Analysts expect Legend Biotech to post earnings of ($0.23) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Legend Biotech (NASDAQ:LEGN) last announced its quarterly earnings results on Monday, March 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.30. The business had revenue of $76.50 million for the quarter, compared to analyst estimates of $95.63 million. Legend Biotech had a negative net margin of 181.75% and a negative return on equity of 37.19%. The company’s revenue for the quarter was up 177.2% on a year-over-year basis. On average, analysts expect Legend Biotech to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Legend Biotech Stock Performance

Shares of NASDAQ:LEGN opened at $45.41 on Monday. The company has a current ratio of 6.92, a quick ratio of 6.83 and a debt-to-equity ratio of 0.22. The company has a market cap of $8.26 billion, a price-to-earnings ratio of -30.68 and a beta of 0.12. Legend Biotech has a 12 month low of $42.08 and a 12 month high of $77.32. The company has a 50-day moving average price of $56.42 and a 200-day moving average price of $59.26.

Wall Street Analysts Forecast Growth

LEGN has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $87.00 price objective on shares of Legend Biotech in a report on Tuesday, April 23rd. Scotiabank upgraded shares of Legend Biotech from a “sector perform” rating to a “sector outperform” rating and set a $65.00 price target on the stock in a report on Wednesday, April 17th. Barclays upped their price objective on shares of Legend Biotech from $93.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, January 24th. Raymond James assumed coverage on shares of Legend Biotech in a research note on Wednesday, March 13th. They set an “outperform” rating and a $86.00 target price on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $85.00 price objective on shares of Legend Biotech in a report on Thursday, March 7th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $82.64.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).